Full text is available at the source.
A novel GIP analogue, ZP 4165, enhances glucagon‐like peptide‐1‐induced body weight loss and improves glycaemic control in rodents
A new GIP-like drug, ZP4165, boosts weight loss and blood sugar control caused by GLP-1 in rodents
AI simplified
Abstract
ZP4165 reduced glycated haemoglobin levels in diabetic mice after 4 weeks of dosing.
- ZP4165 demonstrated insulin-releasing effects in rats during glucose testing.
- The GIP analogue did not affect body weight in obese mice but enhanced weight loss induced by a GLP-1 agonist.
- In diabetic db/db mice, ZP4165 improved glycaemic control to a degree comparable to the GLP-1 agonist after 4 weeks.
- The findings suggest that ZP4165 may enhance the effects of GLP-1 therapy for managing obesity and type 2 diabetes.
AI simplified